The bioavailability of IV methylprednisolone and oral prednisone in multiple sclerosis

被引：65

作者：

Morrow, SA

Stoian, CA

Dmitrovic, J

Chan, SC

Metz, LM

机构：

[1] Univ Western Ontario, Dept Clin Neurosci, London, ON, Canada

[2] Univ Calgary, Dept Clin Neurosci, Calgary, AB, Canada

[3] Univ Calgary, Dept Pharmacol & Therapeut, Calgary, AB, Canada

[4] Univ Calgary, Dept Pathol & Lab Med, Calgary, AB, Canada

来源：

NEUROLOGY | 2004年 / 63卷 / 06期

关键词：

D O I：

10.1212/01.WNL.0000138572.82125.F5

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

Oral prednisone (1)might be a convenient, inexpensive alternative to IV methylprednisolone ( IVMP) if the bioequivalent dose was known. We compared the total amount of steroid absorbed after 1250 mg oral prednisone vs 1 gram IVMP in 16 patients with multiple sclerosis (MS). At 24 hours, the mean area under the concentration-time curve (AUC), the main component of bioavailability, did not differ between groups (p=0.122). This suggests that the amount of absorbed corticosteroid is similar after either steroid at these doses.

引用

页码：1079 / 1080

页数：2

共 10 条

[1] INFLUENCE OF ROUTE OF ADMINISTRATION ON THE PHARMACOKINETICS OF METHYLPREDNISOLONE [J].

ANTAL, EJ ;

WRIGHT, CE ;

GILLESPIE, WR ;

ALBERT, KS .

JOURNAL OF PHARMACOKINETICS AND BIOPHARMACEUTICS, 1983, 11 (06) :561-576

[2] Randomised trial of oral and intravenous methylprednisolone in acute relapses of multiple sclerosis [J].

Barnes, D ;

Hughes, RAC ;

Morris, RW ;

WadeJones, O ;

Brown, P ;

Britton, T ;

Francis, DA ;

Perkin, GD ;

Rudge, P ;

Swash, M ;

Katifi, H ;

Farmer, S ;

Frankel, J .

LANCET, 1997, 349 (9056) :902-906

[3] THE EFFECT OF CORTICOSTEROIDS FOR ACUTE OPTIC NEURITIS ON THE SUBSEQUENT DEVELOPMENT OF MULTIPLE-SCLEROSIS [J].

BECK, RW ;

CLEARY, PA ;

TROBE, JD ;

KAUFMAN, DI ;

KUPERSMITH, MJ ;

PATY, DW ;

BROWN, CH .

NEW ENGLAND JOURNAL OF MEDICINE, 1993, 329 (24) :1764-1769

[4] A RANDOMIZED, CONTROLLED TRIAL OF CORTICOSTEROIDS IN THE TREATMENT OF ACUTE OPTIC NEURITIS [J].

BECK, RW ;

CLEARY, PA ;

ANDERSON, MM ;

KELTNER, JL ;

SHULTS, WT ;

KAUFMAN, DI ;

BUCKLEY, EG ;

CORBETT, JJ ;

KUPERSMITH, MJ ;

MILLER, NR ;

SAVINO, PJ ;

GUY, JR ;

TROBE, JD ;

MCCRARY, JA ;

SMITH, CH ;

CHROUSOS, GA ;

THOMPSON, HS ;

KATZ, BJ ;

BRODSKY, MC ;

GOODWIN, JA ;

ATWELL, CW .

NEW ENGLAND JOURNAL OF MEDICINE, 1992, 326 (09) :581-588

[5] HIGH-DOSE ORAL METHYLPREDNISOLONE IN PATIENTS WITH RHEUMATOID-ARTHRITIS - PHARMACOKINETICS AND CLINICAL-RESPONSE [J].

HAYBALL, PJ ;

COSH, DG ;

AHERN, MJ ;

SCHULTZ, DW ;

ROBERTSTHOMSON, PJ .

EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1992, 42 (01) :85-88

[6] Trials to assess equivalence: The importance of rigorous methods [J].

Jones, E ;

Jarvis, P ;

Lewis, JA ;

Ebbutt, AF .

BMJ-BRITISH MEDICAL JOURNAL, 1996, 313 (7048) :36-39

[7] Gastric tolerance of high-dose pulse oral prednisone in multiple sclerosis [J].

Metz, LM ;

Sabuda, D ;

Hilsden, RJ ;

Enns, R ;

Meddings, JB .

NEUROLOGY, 1999, 53 (09) :2093-2096

[8]

METZ LM, 2000, INT J MS CARE, V2

[9]

STUBBS SS, 1975, TRANSPLANT P, V7, P11

[10] RELATIVE BIOAVAILABILITY OF PREDNISONE AND PREDNISOLONE IN MAN [J].

TSE, FLS ;

WELLING, PG .

JOURNAL OF PHARMACY AND PHARMACOLOGY, 1979, 31 (07) :492-493

← 1 →